iBio's business strategy is to broadly participate in the markets that the iBio Technology platform addresses.

Lab column 2018 04 11 10.38.29
  • Early-stage Biotech companies
  • Large pharma
  • Universities and University commercial spin-outs
  • Government Agencies- DARPA, NIH
  • International Clients
    • Tech transfer and facilities development in emerging countries – Brazil, South Africa
    • New biotherapeutic development – Japan, China


Monoclonal Antibodies

Medical Devices